details

A rare disease that mainly affects younger people and has so far meant a poor prognosis - this combination characterizes fusion-driven sarcomas. An interdisciplinary team has been researching this aggressive tumor type for three years in the HEROES-AYA project. Strong patient participation is essential for the success of the project. The first partial results are available, a clinical trial has already been decoupled - and the interim review was so successful that the entire planned funding amount of 18 million euros will flow.

How did the researchers achieve this interim success? How does the cooperation within HEROES-AYA work and how does the project create new perspectives for young people with rare cancers? You can read the full text (in German) here.

The article is taken from the current issue of our magazine Connect, which is dedicated to the 20th anniversary of NCT Heidelberg under the title 20plusZukunft. Every two weeks, we present a Connect highlight from the magazine.

The magazine is available to take away at many locations in the NCT Heidelberg building. Please help yourself and grab your own copy!

Would you like to read the entire Connect magazine? You can order it free of charge here or download it as a PDF file.

Please note: The Connect magazine is available in German only.